TRUST IN TRIALS
EUROPA STAGE – 11:15-12:15
- What role do clinical trials play in EU medicines regulation?
- How can we encourage cooperation between universities and private bodies to facilitate clinical trials?
- Is it ethical for physicians to prescribe cannabis-based medicines without clinical trials to back their efficiency and safety?
- Are clinical trials an absolute necessity for regulatory authorisation and doctors’ willingness to prescribe in Europe?
- How are medical cannabis patents enforceable?
CHAIR: Hélène Moore
Hélène Moore is a dynamic pharmaceutical and life sciences executive with substantial experience in the North American and European markets. Hélène is currently leading corporate development for Aurora Europe GmbH in France. She is also the founder and CEO of pharmBD, a boutique-style business development firm dedicated to the life sciences industry.
Hélène has a wealth of experience in deal-making for companies in the pharmaceutical, medical devices and medical cannabis industries, across territories such as the Americas, Europe, Latin America, the Middle East and South Korea.
Rikke Jacobson is CEO of Cannabis Danmark, a non-profit organisation that collects and provides information about medical cannabis to all stakeholders involved with this topic in Denmark – politicians, ministries, physicians, patients, growers and business in the industry.
The goal of the organisation is to get the highest quality cannabis to the lowest prices and facilitate research in high standard. Rikke lobbied to implement the 4-year pilot programme in Denmark regarding medicial cannabis and helped introduce Denmark’s agriculture and food organisation to the issue in 2015.
Dr. David McDowell
Dr David McDowell was employed as a consultant in pain management at Salford Royal Hospital NHS Trust in England from 1995 to 2011. Since 2011 he has been working as a full time specialist pain consultant in the independent health sector.
In 2016, Dr McDowell developed an interest in the use of medical cannabis to treat chronic pain. After the regulation of medical cannabis in the UK in November 2018, Dr McDowell became the first doctor to give a prescription for medical cannabis.
Catherine identifies opportunities for clinical research partnerships that fulfill Tilray’s goal of advancing knowledge of cannabinoid science by partnering with physicians and medical institutions to generate data that will inform best treatment practices.
Prior to joining Tilray, Catherine led a venture philanthropic fund addressing the lack of adequate drugs and devices to treat paediatric epilepsy. Before that, she served as a post-doctoral fellow at UC San Francisco where she established GW Pharmaceuticals’ Expanded Access Investigational New Drug Application (IND) for Epidiolex for the treatment of children with severe medically refractory epilepsy.
Rosemary Mazanet, M.D., PhD is the Chief Scientific Officer for Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States. In her role, Dr. Mazanet leads the Company in developing innovative cannabis-based medicines using rigorous scientific techniques and data analytics.
Dr. Mazanet trained as a Doctor of Internal Medicine at Brigham and Women’s Hospital, and in oncology at the Dana Farber Cancer Institute, both affiliates of the Harvard Medical School.